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Image in Focus 
Figure 1. A – Gross appearance of the calvarium obtained at autopsy showing multiple bone lytic lesions (“punched 
out,” “pepper pot skull,” or “raindrop skull”) ranging from 0.5 cm to 2.5 cm in diameter, filled by fleshy, soft 
tissue. B – Computed tomography (CT) of the brain (3D reformation) showing multiple lytic lesions, which are more 
prominent in the occipital area. C – Axial brain CT showing bone lytic lesions invading soft tissues.
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Multiple myeloma (MM) is a neoplastic proliferation 
of a clonal population of plasma cells, which produces 
monoclonal protein (immunoglobulin G [IgG], IgA, 
and light chain protein κ or λ are the most common).1 
The plasma cells neoplasia affects the bones—including 
the skull—leading to extensive skeletal destruction due 
to osteolytic lesions and osteopenia, with consequent 
pathologic fractures.2 Other cardinal features of 
MM are bone pain, fatigue, weight loss, anemia, 
hypercalcemia, hypergammaglobulinemia with a 
monoclonal protein in serum or in the urine, renal 
insufficiency, and secondary infections.1
MM accounts for almost 1% and 10% of all 
neoplasia and hematologic malignancies, respectively, 
and has a worldwide distribution.1 In the United 
States, the incidence of MM is approximately 4–5 per 
100,000 inhabitants.3 In Brazil, the incidence is not 
well known. In a survey involving 16 different Brazilian 
health centers, Hungria et al.4 found 1,112 cases of 
MM, from 1998 to 2004. Currently, The International 
Myeloma Foundation computes that there are 
approximately 30,000 MM patients under treatment 
in Brazil.5 MM is two to three times more common 
in Africans and African-Americans, with the lowest 
incidence among Japanese and Mexicans. The ratio 
of men: women is approximately 1.4:1. The neoplasia 
affects elderly people, with a median age of 66 years.6,7 
Some of the risk factors for MM are older age, 
environmental exposure to radiation, organic solvents 
(such as benzene), herbicides and insecticides, and 
genetic factors (familial cases, ethnicity, variations at 
the 3p22.1 or 7p15.3 loci).6,8
The lytic lesions are the main finding of MM, 
which were described in the first reports of the disease 
by Solly9 and Macintyre10 as fractured bones were 
replaced by gelatiniform, a reddish and unctuous 
substance.9,10 Later, Wright11 associated MM with 
neoplastic proliferation of plasma cells. The myeloma 
lytic lesions are in agreement with the Paget’s12 concept 
of “seed and soil,” where the neoplastic cells (“seeds”: 
neoplastic plasma cells) have tropism for certain 
microenvironments (“soil”: bones).
The pathogenesis of the bone lytic lesions in the 
MM is complex and involves an imbalance between 
osteoblastic and osteoclastic functions. The osteoclastic 
activation is increased in MM, with bone reabsorption 
stimulated by the receptor activator of nuclear factor 
κ-β ligand (RANKL). The RANKL is overexpressed by 
osteoblasts and plasma cells, which are associated 
with low levels of osteoprotegerin, the RANKL decoy 
receptor. In addition, bone stromal cells produce 
factors that activate the osteoclastic function, such as 
interleukin-3 (IL-3), IL-6, macrophage inflammatory 
protein-1 alpha (MIP-1α) and stromal derived factor 1α 
(SDF-1α).13,14 The osteoblast differentiation is inhibited 
by an increased expression of IL-3, IL-7 and dickkopf 
1 (DKK1).15
Figure 1 refers to the case of a 62-year-old 
woman who presented headache, fatigue, weight 
loss, episodes of blurred vision and diplopia, bone 
pain, and the appearance of numerous nodules in the 
scalp. The laboratory work-up revealed hypercalcemia, 
azotemia, multiple lytic bone lesions (skull, sternum, 
ribs, vertebrae, ilium), and urinary kappa Bence-Jones 
protein. The bone marrow biopsy showed infiltration 
of atypical plasma cells, with monoclonal expression of 
κ-light chain. The patient died due to a sudden cardiac 
arrest, which the autopsy revealed to be caused by a 
massive pulmonary embolism.
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